Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on December 2, 2002

Hypertension. 2002
Published online before print December 2, 2002, doi: 10.1161/01.HYP.0000046496.73852.53
A more recent version of this article appeared on January 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
41/1/119    most recent
01.HYP.0000046496.73852.53v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Zander, K.
Right arrow Articles by de Leeuw, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Zander, K.
Right arrow Articles by de Leeuw, P. W.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Cardiovascular Pharmacology
Right arrow Hypertension - basic studies
Right arrow Angiography
Right arrow Other Vascular biology

Submitted on July 1, 2002
Revised on July 30, 2002

Does Brain Natriuretic Peptide Have a Direct Renal Effect in Human Hypertensives?

Kim van der Zander; Alphons J.H.M. Houben; Abraham A. Kroon; Thomas K.A. Wierema; Monique J.M.J. Fuss-Lejeune; Derk Koster; and Peter W. de Leeuw*

From the Departments of Medicine and Radiology, Cardiovascular Research Institute Maastricht, and University Hospital Maastricht, The Netherlands.

* To whom correspondence should be addressed. E-mail: p.deleeuw{at}intmed.unimaas.nl.

Abstract—Systemic infusion of brain natriuretic peptide (BNP) stimulates natriuresis and diuresis but has variable effects on the renal vasculature. In this study, we investigated whether BNP has any direct effects on the kidney in hypertensive patients. Three stepwise increasing doses of BNP (60, 120, and 180 pmol/min) or placebo were infused into the renal artery of 26 hypertensive patients. Renal blood flow was determined with the 133Xenon washout technique. Before and after infusion of BNP, arterial and venous blood samples were taken for cGMP, renin, and creatinine concentration. Intra-arterial blood pressure and heart rate were monitored continuously. Intrarenal BNP infusion did not induce significant changes in renal blood flow despite increases in circulating levels of cGMP. The latter, however, was not associated with changes in the cGMP gradient across the kidney. In addition, we did not find any BNP-related changes in the secretion of active renin and in creatinine extraction. At the highest dose, heart rate increased after BNP infusion without a change in mean intra-arterial blood pressure. In conclusion, this study suggests that at least in hypertensive subjects, BNP has no direct intrarenal hemodynamic effects and that the rise in circulating cGMP without changes in net renal extraction of this second messenger is related to a primary extrarenal target of BNP.


Key words: natriuretic peptides • vasodilation • hypertension, renal • human • kidney • hemodynamics • vasoconstriction • hormones